{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:16:32Z","timestamp":1782209792639,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Celltrion, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12325-021-01834-3","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T02:02:21Z","timestamp":1626055341000},"page":"4366-4387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct02557295","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jae Hee","family":"Cheon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongsu","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoun Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Hyun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Bee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"1834_CR1","unstructured":"European Medicines Agency. Inflectra summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inflectra-epar-product-information_en.pdf. Accessed 3 Jun 2021."},{"key":"1834_CR2","unstructured":"European Medicines Agency. Remsima summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed 3 Jun 2021."},{"key":"1834_CR3","unstructured":"US Food and Drug Administration. Inflectra prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s009lbl.pdf. Accessed 3 Jun 2021."},{"key":"1834_CR4","unstructured":"Ministry of Food and Drug Safety. Biological products: recombinant DNA products, Celltrion, Inc. https:\/\/www.mfds.go.kr\/eng\/brd\/m_30\/view.do?seq=69797. Accessed 3 Jun 2021."},{"key":"1834_CR5","unstructured":"Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea. 2012. http:\/\/www.gabionline.net\/Biosimilars\/News\/Biosimilar-monoclonal-antibody-approved-in-Korea. Accessed 3 Jun 2021."},{"key":"1834_CR6","unstructured":"European Medicines Agency. Remicade summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 3 Jun 2021."},{"key":"1834_CR7","unstructured":"US Food and Drug Administration. Remicade prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103772s5389s5391s5394lbl.pdf. Accessed 3 Jun 2021."},{"issue":"5","key":"1834_CR8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2021;60(5):2277\u201387.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1834_CR11","first-page":"MR000012","volume":"2011","author":"J Odgaard-Jensen","year":"2011","unstructured":"Odgaard-Jensen J, Vist GE, Timmer A, et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2011;2011(4):MR000012.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9977","key":"1834_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(15)60742-5","volume":"385","author":"DS Jones","year":"2015","unstructured":"Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet. 2015;385(9977):1502\u20133.","journal-title":"Lancet"},{"issue":"5","key":"1834_CR13","doi-asserted-by":"publisher","first-page":"e1001026","DOI":"10.1371\/journal.pmed.1001026","volume":"8","author":"S Golder","year":"2011","unstructured":"Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011;8(5):e1001026.","journal-title":"PLoS Med"},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.clinthera.2007.07.004","volume":"29 Spec No","author":"RJ Ligthelm","year":"2007","unstructured":"Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec No:1284\u201392.","journal-title":"Clin Ther"},{"issue":"4","key":"1834_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40259-020-00421-2","volume":"34","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34(4):513\u201328.","journal-title":"BioDrugs"},{"issue":"2","key":"1834_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, D\u00f6rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374.","journal-title":"Ann Rheum Dis"},{"key":"1834_CR17","unstructured":"European Medicines Agency. Remsima public assessment report. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/remsima-epar-public-assessment-report_en.pdf. Accessed 3 Jun 2021."},{"key":"1834_CR18","unstructured":"European Medicines Agency. Inflectra public assessment report. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/inflectra-epar-public-assessment-report_en.pdf. Accessed 3 Jun 2021."},{"issue":"6","key":"1834_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/joim.12880","volume":"285","author":"GL Goll","year":"2019","unstructured":"Goll GL, J\u00f8rgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653\u201369.","journal-title":"J Intern Med"},{"issue":"2","key":"1834_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1834_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1834_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237\u201345.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5217\/ir.2019.00030","volume":"17","author":"T Nakagawa","year":"2019","unstructured":"Nakagawa T, Kobayashi T, Nishikawa K, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504\u201315.","journal-title":"Intest Res"},{"issue":"2","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","volume":"23","author":"G Fiorino","year":"2017","unstructured":"Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233\u201343.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"1834_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3899\/jrheum.140538","volume":"42","author":"D Choquette","year":"2015","unstructured":"Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol. 2015;42(7):1105.","journal-title":"J Rheumatol"},{"issue":"8","key":"1834_CR26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/acr.22290","volume":"66","author":"C Thorne","year":"2014","unstructured":"Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res. 2014;66(8):1142\u201351.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40261-020-00907-5","volume":"40","author":"TH Kim","year":"2020","unstructured":"Kim TH, Lee SS, Park W, et al. A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Drug Investig. 2020;40(6):541\u201353.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1834_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.55563\/clinexprheumatol\/z0va6o","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee E, Lee SK, et al. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. 2020;38(2):267\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40259-019-00393-y","volume":"34","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee E, Lee SK, et al. Retention rate and safety of biosimilar CT-P13 in rheumatoid arthritis: data from the Korean College of Rheumatology Biologics registry. BioDrugs. 2020;34(1):89\u201398.","journal-title":"BioDrugs"},{"issue":"2","key":"1834_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","volume":"31","author":"P Kurki","year":"2017","unstructured":"Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83\u201391.","journal-title":"BioDrugs"},{"issue":"11","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1097\/MIB.0000000000001237","volume":"23","author":"L Gonczi","year":"2017","unstructured":"Gonczi L, Gecse KB, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017;23(11):1908\u201315.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14740338.2017.1323330","volume":"16","author":"A B\u00e1lint","year":"2017","unstructured":"B\u00e1lint A, Rutka M, V\u00e9gh Z, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin Drug Saf. 2017;16(8):885\u201390.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","volume":"10","author":"KB Gecse","year":"2016","unstructured":"Gecse KB, Lov\u00e1sz BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133\u201340.","journal-title":"J Crohns Colitis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01834-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T18:34:22Z","timestamp":1672770862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01834-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01834-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}